CALL for ABSTRACTS

Guidelines and Procedures

Meeting Dates: October 19–24, 2018

McCormick Place, Chicago, IL

www.rheumatology.org/Annual-Meeting/Abstracts
This is your complete guide to submitting an abstract for the 2018 ACR/ARHP Annual Meeting in Chicago, IL, October 19–24, 2018. Please read this entire guide before you begin the submission process.

The American College of Rheumatology (ACR) and the Association of Rheumatology Health Professionals (ARHP) invite you to submit an abstract and take advantage of the opportunity to have your work peer reviewed by experts in the field. If accepted, your abstract will be published in an online supplement of the *Arthritis & Rheumatology* journal and displayed in the distinguished international venue of the 2018 ACR/ARHP Annual Meeting.

**NEW THIS YEAR!**
- All authors will be notified of abstract acceptance or rejection.
- A “designated secondary contact author” must be indicated during submission.
- Many category names and descriptions have changed—read carefully!
- Opportunity for presenting authors to pre-record an audio overview of a poster.

**IMPORTANT DATES**

**Abstract Submission**
- **Tuesday, April 10** - Abstract Submission Site Opens
- **Tuesday, June 5** - Abstract Submission Site Closes (NOON ET)
- **Mid-August** - Author Notification
- **Thursday, August 16** - Accepted Abstract Withdrawal Deadline
- **Thursday, August 16** - Late-Breaking Abstract Submission Site Opens
- **Thursday, September 13** - Late-Breaking Abstract Submission Site Closes (NOON ET)

**Registration and Housing**
- **Wednesday, May 16** - Member Registration and Housing Opens
- **Wednesday, May 30** - Non-Member Registration and Housing Opens
- **Wednesday, August 1** - Early Bird Registration Rate Deadline
- **Wednesday, October 3** - Advance Registration Rate Deadline

**Annual Meeting**
- **October 20** - Abstract Embargo Lifted (4:30 PM CT)
- **October 21–23** - ACR/ARHP Abstract Poster Sessions/Tours (9:00–11:00 AM CT)
  - ACR Plenary Abstract Sessions (11:00 AM–12:30 PM CT)
  - ACR/ARHP Abstract Concurrent/Combined Sessions (2:30–4:00 and 4:30–6:00 PM CT)
- **October 24** - ACR/ARHP Abstract Concurrent/Combined Sessions (9:00–10:30 AM and 11:00 AM–12:30 PM CT)
# TABLE OF CONTENTS

## Part I: Abstract Submission

- ACR Call for Abstracts .................................................................................................................. 5
- Eligibility ...................................................................................................................................... 5
- Abstract Submitter Expectations ................................................................................................. 5
- Submitting an ACR Abstract ....................................................................................................... 6
- ACR Abstract Submission Processing Fee .................................................................................. 6
- 2018 ACR Abstract Submission Categories .............................................................................. 6
- For Young Investigators: ACR/ARHP Basic Research Conference and Clinical Research Conference Abstracts ................................................................. 8
- ARHP Call for Abstracts .............................................................................................................. 9
- Submitting an ARHP Abstract ..................................................................................................... 9
- ARHP Abstract Submission Processing Fee ............................................................................... 9
- 2018 ARHP Abstract Submission Categories .......................................................................... 10
- For Students, Residents, and Fellows-in-Training .................................................................... 10
- Rheumatology Research Foundation Abstract Awards ............................................................ 10
- Abstract Submission Instructions/Guidelines ............................................................................ 11
- Submitting an Abstract ............................................................................................................... 11
- Abbreviations ............................................................................................................................. 11
- Abstract Character Limit ............................................................................................................. 11
- Abstract Title ............................................................................................................................... 11
- Authors ....................................................................................................................................... 12
- Content ........................................................................................................................................ 12
- Images, Tables, and Graphics .................................................................................................... 12
- Disclosure Policy ........................................................................................................................ 12
- Disclosure Statement Submission Process ................................................................................ 13
- Involvement of Individuals Not Listed as Authors ................................................................. 14
- Multiple Submissions of the Same Study ................................................................................ 14
- Presentation Formats .................................................................................................................. 14
- Product Name Usage .................................................................................................................. 14
- Research Involving Animals ....................................................................................................... 14
- Research Involving Human Subjects ....................................................................................... 14
- Revisions ..................................................................................................................................... 14
- Study Design Abstract Submissions .......................................................................................... 15
- Study Sponsor Statements ......................................................................................................... 15
- Withdrawals ............................................................................................................................... 15
- Need Help? ................................................................................................................................. 15
- Abstract Review and Notification ............................................................................................. 15
- Abstract Review ........................................................................................................................ 15
- Abstract Acceptance/Rejection Notifications ......................................................................... 15
- Registration & Housing ............................................................................................................ 16

**Abstract Submission Deadline: June 5, noon ET!**

[www.rheumatology.org/Annual-Meeting/Abstracts](http://www.rheumatology.org/Annual-Meeting/Abstracts)
# TABLE OF CONTENTS

## Part II: Abstract Presentation
- Abstract Embargo Policy .............................................. 16
- Presentation Formats ................................................. 16
- Oral Abstract Presentation .......................................... 16
- Oral Presentation Slide Requirements .......................... 17
- Poster Abstract Presentation ....................................... 17
- Poster Specifications .................................................. 17
- ACR Poster Presenter Expectations ............................... 18
- Guided Poster Tours ................................................... 18
- Presenting Author Responsibilities ............................... 18
- ACR Abstract Session Schedule Conflicts Policy .......... 19
- Presenting Author Affirmations ................................... 19
- ACCME Standard and ACR Policy Regarding Third-Party Bias ......................................................... 19
- Publication ................................................................. 19

## Part III: Abstract Permissions Policies
- Copyright Policy ......................................................... 19
- Abstract Permissions and Reprints ............................... 20
- Approval Process for ACR Abstracts ............................. 20
- Approval Process for ACR Posters ............................... 20
- Reproducing ACR Abstracts and Posters for Dissemination Prior to the Annual Meeting .................. 21
- Reproducing ACR Abstracts and Posters for Dissemination During the Annual Meeting .................... 21
- Reproducing ACR Abstracts and Posters for Dissemination After the Annual Meeting .................... 21
- Media ................................................................. 21
- Photographs and Video Recording Policy ....................... 22
- Disclosure and Content Use ....................................... 22
- Use of the ACR Name ................................................ 22
- Use of the ACR Disclosure Key ................................... 22
- Use of the ACR Scientific Program Content ................. 22
- Part IV: ACR Call for Late-Breaking Abstracts .............. 22

---

*Icon denotes new classes and procedures for 2018.*

*Icon denotes course and category changes, and other important information.*

---

**ABSTRACT SUBMISSION DEADLINE:** June 5, noon ET!

[www.rheumatology.org/Annual-Meeting/Abstracts](http://www.rheumatology.org/Annual-Meeting/Abstracts)
PART I: ABSTRACT SUBMISSION

ACR Call for Abstracts
The ACR Annual Meeting program includes content related to the clinical practice and teaching of rheumatology. The program includes abstracts covering the basic and translational science that contributes to the understanding of disease pathogenesis, therapy mechanisms and efficacy, and healthcare delivery to patients with musculoskeletal and rheumatic diseases.

Eligibility

Who Is Eligible to Submit?
• Members and non-members of the ACR and ARHP are eligible to submit an abstract.

What Types of Abstracts Are Eligible for Submission?
• Abstracts describing original basic and clinical science related to the broad area of rheumatic diseases may be submitted.
• If the abstract reports results of a clinical trial, you will be required to identify the trial phase.
• Any work with human or animal subjects reported in submitted abstracts must comply with the guiding principles for experimental procedures found in the Declaration of Helsinki of the World Medical Association.

What Types of Abstracts Are Not Eligible for Submission?
• Abstracts that report work that has been accepted for publication as a manuscript (e.g., full-length article, brief report, case report, concise communication or letter to the editor, etc.) prior to the ACR/ARHP submission deadline of noon ET on Tuesday, June 5, 2018 are ineligible for consideration.
• Abstracts should not report results that have been previously presented at an ACR/ARHP Annual Meeting.
• Multiple abstracts may not be submitted for one study.
• Abstracts submitted for the ARHP program may not be concurrently submitted to the ACR program.
• Abstracts that appear as more than one version of a single study will be rejected.
• Case reports are not considered appropriate and will not be reviewed.
• Abstracts not accepted by the main abstract review deadline should not be re-submitted to the late-breaking category.

Abstract Submitter Expectations
• Pay a processing fee for each abstract submission. Abstract processing fees must be in U.S. funds and are non-refundable. The ACR will provide a receipt, but does not supply invoices for payments received.
• By submitting your abstract, you agree to present the abstract if it is selected for presentation during an oral or poster abstract presentation at the 2018 Annual Meeting in Chicago, IL.
• If your abstract can only be presented as a poster, please check the appropriate box during the submission process. This is your only opportunity to indicate your preference for a poster.

ABSTRACT SUBMISSION DEADLINE: June 5, noon ET! www.rheumatology.org/Annual-Meeting/Abstracts
1 Abstract Submission continued

- Select the most appropriate category to submit the abstract based on the most relevant disease/topic.
- No changes may be made to a submission after the deadline of June 5 at noon ET. However, you will be able to access the submission portal to view your completed abstract submission. You may print a copy of your submission fee receipt.

**NEW Optional for submitters:** Opportunity for presenting author to pre-record an up to three-minute audio overview of a poster for the 2018 meeting. Details will be provided upon abstract acceptance.

**Submitting an ACR Abstract**
Review all submission instructions provided in this guide before submitting an abstract. Visit the [online submission site](#) to get started.

**ACR Abstract Submission Processing Fee**
Each ACR abstract submitted has a mandatory $70 processing fee. The ACR accepts electronic payment only in the form of MasterCard, Visa, or American Express. Abstract processing fees must be in U.S. funds. All fees are non-refundable—no exceptions. Rejection or withdrawal of an abstract will not result in a refund.

**SUBMISSION DEADLINE:** Tuesday, June 5, 2018, noon Eastern Time—no exceptions. No changes may be made to your submission, including author information, after the deadline.

**2018 ACR Abstract Submission Categories**
Abstract categories identify areas of research to be presented at the Annual Meeting. Each year, categories are determined by the planning committee and category co-chairs. Reviewers are assigned before the review process begins.

---

**2018 category names and descriptions have changed. Please read carefully.**

**Summary of category name changes:**

- **Biology and Pathology of Bone and Joint** is now **Osteoarthritis and Joint Biology – Basic Science**. Metabolic bone disease studies should be submitted to #28.
- **Pain – Basic Aspects** and **Pain – Clinical Aspects** have been combined into **Pain Mechanisms – Basic and Clinical Science**.
- **Rheumatoid Arthritis – Clinical Aspects** has been renamed **Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes**.
- **Rheumatoid Arthritis – Small Molecules, Biologics, and Gene Therapy** has been renamed **Rheumatoid Arthritis – Treatments**.
- **Vasculitis** has been separated into two categories, **Vasculitis – ANCA-Associated** and **Vasculitis – Non-ANCA-Associated and Related Disorders**.

---
Basic Science

1. **B Cell Biology and Targets in Autoimmune and Inflammatory Disease**: B lymphocyte differentiation and activation, B cell subsets, plasma cells, autoantigens, and autoreactive B cells

2. **Cytokines and Cell Trafficking**: Cytokines, chemokines, cytokine and chemokine receptors, signal transduction pathways, cell-cell interactions, adhesion molecules, cell matrix interactions, and matrix properties

3. **Genetics, Genomics and Proteomics**: Techniques, strategies and observations related to genetic susceptibility of disease, gene expression, bioinformatics and systems biology

4. **Innate Immunity**: Dendritic cells, neutrophils, macrophages, NK cells, innate host defense, pattern recognition receptors and their ligands, complement, Fc receptors, and autoinflammation

5. **NEW Osteoarthritis and Joint Biology – Basic Science**: Joint biology and biochemistry, cartilage and chondrocyte biology, and basic human and animal studies on the pathogenesis of osteoarthritis

6. **Pediatric Rheumatology – Basic Science**: Pathogenesis, genetics and genomics of pediatric rheumatologic conditions and other studies on disease mechanisms relevant to pediatric conditions

7. **Rheumatoid Arthritis – Animal Models**: Animal models of inflammatory synovitis, pathogenetic mechanisms, genetic determinants, immune cell populations, gene expression and treatment

8. **Rheumatoid Arthritis – Etiology and Pathogenesis**: Etiology; pathogenesis; genetics; genomics and related molecular analyses; disease susceptibility; molecular and cellular abnormalities; and microbiome and environmental triggers of rheumatoid arthritis (*These studies focus on human disease and involve human subjects and/or samples*)

9. **Spondyloarthritis Including Psoriatic Arthritis – Basic Science**: Pathogenesis, genetics, and genomics of spondyloarthritis, including psoriatic arthritis and reactive arthritis, and animal models of spondyloarthritis


11. **Systemic Lupus Erythematosus – Etiology and Pathogenesis**: Etiology; pathogenesis; genetics; genomics and related molecular analyses; disease susceptibility; molecular and cellular abnormalities; and microbiome and environmental triggers of SLE (*These studies focus on human disease and involve human subjects and/or samples*)

12. **Systemic Sclerosis and Related Disorders – Basic Science**: Pathogenesis, genetics, and genomics of systemic sclerosis, Raynaud’s phenomenon and other fibrosing syndromes, and animal models of systemic sclerosis and fibrosis

13. **T Cell Biology and Targets in Autoimmune and Inflammatory Disease**: T lymphocyte differentiation and activation, T cell subsets, antigen recognition, autoreactive T cells, cognate cell interactions, and organogenesis

Clinical

14. **Antiphospholipid Syndrome**: Pathogenesis, diagnosis, clinical manifestations, outcomes, and treatment of antiphospholipid syndrome

15. **Education**: Research on curriculum design and implementation; educational research projects; and outcomes research on physician and trainee education, including associated health training

16. **Epidemiology and Public Health**: Studies of trends and risk factors for development and outcomes of rheumatic diseases, typically using population-based databases or disease registries; observational or intervention studies related to the natural history or prevention of rheumatic disease

**ABSTRACT SUBMISSION DEADLINE: June 5, noon ET!**

[www.rheumatology.org/Annual-Meeting/Abstracts](http://www.rheumatology.org/Annual-Meeting/Abstracts)
1. **Fibromyalgia and Other Clinical Pain Syndromes**: Fibromyalgia, regional pain syndromes, and local diseases of muscle, ligament and tendon

2. **Healthcare Disparities in Rheumatology**: Population-specific differences in the presentation, features, treatment, access and outcomes of rheumatologic disease

3. **Health Services Research**: Delivery of care affecting patients with rheumatic disease; health systems and health care economic and utilization analysis *(combined with ARHP Health Services category during review)*

4. **Imaging of Rheumatic Diseases**: Abstracts primarily focused on radiography, nuclear medicine, magnetic resonance imaging (MRI), ultrasound, computed tomography (CT), or novel imaging modalities

5. **Infections and Rheumatic Disease**: Musculoskeletal manifestations of infectious disease, infections and vaccinations in patients with rheumatic diseases *(For infections resulting from or related to a specific rheumatic disease, please submit to the appropriate disease category.)*

6. **Measures and Measurement of Healthcare Quality**: Development and assessment of tools to measure or quantify healthcare processes, outcomes, organizational structures and/or systems relating to healthcare goals, including safety, effectiveness, equity and timeliness

7. **Metabolic and Crystal Arthropathies – Basic and Clinical Science**: Pathogenesis, diagnosis, clinical manifestations, outcomes, and treatment of gout and other crystal-induced and metabolic arthropathies

8. **Miscellaneous Rheumatic and Inflammatory Diseases**: Rheumatic manifestations specific to either a single etiology, organ system, and therapy of less common and even rare illnesses not included in other categories *(e.g., immunotherapy rheumatic complication, autoimmune eye disease, interstitial lung disease with autoimmune features, periodic fever syndromes, RS3PE, reticulohistiocytosis, SAPHO)*

9. **Muscle Biology, Myositis and Myopathies – Basic and Clinical Science**: Muscle biology, inflammatory and non-inflammatory muscle disease

10. **Orthopedics, Low Back Pain and Rehabilitation**: Orthopedic conditions and interventions, physical medicine techniques and outcomes, sports medicine *(combined with ARHP Rehabilitation category during review process)*

11. **Osteoarthritis – Clinical**: Diagnosis, clinical manifestations, outcomes, and treatment of osteoarthritis

12. **Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science**: Pathology, diagnosis, clinical manifestations, outcomes, and treatment of osteoporosis and metabolic bone disease

13. **NEW Pain Mechanisms – Basic and Clinical Science**: Studies on pain mechanisms, animal models of pain, pain physiology, pain evaluation, pain management, and pain-related functional imaging

14. **Patient Outcomes, Preferences, and Attitudes**: Research focused on perceptions, preferences, and attitudes of patients with rheumatic disease as well as patient-reported outcomes

15. **Pediatric Rheumatology – Clinical**: Diagnosis, clinical manifestations, outcomes, and treatment of inflammatory and non-inflammatory pediatric conditions

16. **Reproductive Issues in Rheumatic Disorders**: Biologic mechanisms impacting fertility, pregnancy or fetal outcomes, management of pregnancy and preconception planning in various rheumatic diseases; issues pertaining to fertility in rheumatic disease; HPV infection and vaccinations in rheumatic disease patients

17. **Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes (formerly Rheumatoid Arthritis – Clinical Aspects)**: Presentation, diagnosis, assessment, prognosis, outcomes, and comorbidities of rheumatoid arthritis

35. Sjögren’s Syndrome – Basic and Clinical Science: Pathogenesis, diagnosis, clinical manifestations, outcomes, and treatment of Sjögren’s syndrome

36. Spondyloarthritis Including Psoriatic Arthritis – Clinical: Diagnosis, clinical manifestations, outcomes, and treatment of spondyloarthritis, including psoriatic arthritis and reactive arthritis

37. Systemic Lupus Erythematosus – Clinical: Diagnosis, clinical manifestations, outcomes, and treatment of lupus

38. Systemic Sclerosis and Related Disorders – Clinical: Diagnosis, clinical manifestations, outcomes, and treatment of systemic sclerosis, Raynaud’s and other fibrosing syndromes

39. NEW Vasculitis – ANCA-Associated: Diagnosis, clinical manifestations, outcomes, and treatment of ANCA-associated vasculitis, including granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA), and microscopic polyangiitis (MPA)

40. NEW Vasculitis – Non-ANCA-Associated and Related Disorders: Etiology, pathogenesis, clinical features, epidemiology, clinical trials, and management of the systemic vasculitides and related syndromes, including polymyalgia rheumatica, Behcet’s disease, Kawasaki disease, cryoglobulinemia, and IgG4-related disease

For Young Investigators: ACR/ARHP Basic Research Conference and Clinical Research Conference Abstracts

Eligibility

- Investigators with less than six years of experience are eligible to submit an abstract to the Basic Research Conference (BRC) or Clinical Research Conference (CRC).
- To be considered for inclusion in either conference, submitters must indicate the appropriate submission type before entering the submission site.
- Abstracts must also be submitted to the ACR or ARHP general abstract program. Acceptance to the ACR program is a prerequisite for consideration for the Basic Research Conference or Clinical Research Conference. Acceptance to either conference does not remove the abstract from the ACR general program.
- Abstracts not accepted to the Basic Research Conference or Clinical Research Conference program are still eligible for consideration in the ACR general abstract program.

BRC/CRC Abstract Submission Processing Fee

There is no additional fee to have your abstract considered for the Basic Research or Clinical Research Conferences.

SUBMISSION DEADLINE: Tuesday, June 5, 2018, noon ET—no exceptions. No changes may be made to your submission, including author information, after the deadline.

Format

Accepted abstracts to the Basic Research and Clinical Research Conferences will be presented in oral format during the pre-meeting sessions on Friday–Saturday, October 19–20.
abstract submission continued

Young Investigators’ Basic Research Conference Criteria
Abstracts should address insightful epigenetic characterization of immune-mediated and rheumatic diseases. The ACR encourages abstracts related to evolving concepts of environmental-epigenetic interactions, genetic and metabolic influences on epigenetic pathways related to autoimmunity, epigenetic regulation influencing the interplay between innate immunity and the adaptive immune response, and epigenetic mechanisms and pathways involved in the pathogenesis of immune-mediated and rheumatic diseases.

Young Investigators’ Clinical Research Conference Criteria
Abstracts should be related to outcomes, diagnostics, or therapeutics incorporating mobile health (mHealth), digital tools, or with a technology focus, in both adult and pediatric rheumatic disease. Abstracts may be related to specific disease outcomes and co-morbidities, or they may address methodological issues such as data collection [e.g., technology to efficiently capture PROs, biosensors] and innovative analytic approaches or connections with “big data,” including bioinformatics or clinical informatics.

ARHP Call for Abstracts
The ARHP program reflects the needs and interests of healthcare professionals with an interest in rheumatology-related issues by offering a forum to address significant issues with a multidisciplinary audience. Abstracts will be peer reviewed by a subsection of the ARHP Annual Meeting Program Subcommittee according to subject categories. ARHP abstract sessions will not necessarily be scheduled by individual category.

Submitting an ARHP Abstract
Visit the online submission site to get started.

ARHP Abstract Submission Processing Fee
A $40 processing fee accompanies each ARHP abstract submission. The ARHP accepts electronic payment only in the form of MasterCard, Visa, or American Express. Abstract processing fees must be in U.S. funds and are non-refundable—no exceptions. There are no refunds for rejected or withdrawn abstracts.

SUBMISSION DEADLINE: Tuesday, June 5, 2018, noon Eastern Time—no exceptions. No changes may be made to your submission, including author information, after the deadline.

2018 ARHP Abstract Submission Categories
Abstract categories identify areas of research to be presented at the Annual Meeting. Each year, the abstract scientific categories are determined by the planning committee and category co-chairs. Reviewers are assigned before the review process begins.

41. Clinical Practice/Patient Care: Care of patients, practice management, medication monitoring/adherence, and complementary and alternative strategies.

42. Education/Community Programs: Patient education, professional education, community-based programs, and public health programs.

43. Epidemiology and Public Health: Studies of trends and risk factors for development and outcomes of rheumatic diseases, typically using population-based databases or disease registries; observational or intervention studies related to the natural history or prevention of rheumatic disease

44. Health Services Research: Delivery of care affecting patients with rheumatic disease; health systems and health care economic and utilization analysis [combined with ACR Health Services Research category during review]
Abstract Submission continued

45. **Orthopedics, Low Back Pain, and Rehabilitation** *(formerly Rehabilitation Sciences)*: Orthopedic conditions and interventions, physical/occupational therapy techniques and outcomes, rehabilitation and sports medicine [combined with ACR Orthopedics, Low Back Pain, and Rehabilitation category during review]

46. **Pediatric Rheumatology**: Diagnosis, clinical manifestations, outcomes, and treatment of inflammatory and non-inflammatory pediatric conditions; pediatric practice and patient care

47. **Psychology/Social Sciences**: Social, emotional, and behavioral factors affecting patients, families, and providers

48. **Research Methodology**: Quantitative and qualitative studies, new assessment tools and methodology, new analytical techniques and research study management

For Students, Residents, and Fellows-in-Training

The ACR and ARHP encourage the submission of abstracts by presenting authors who are pre-doctoral and post-doctoral students, residents, medical students, or fellows-in-training. Please check the box on the submission site to indicate your training status.

**Rheumatology Research Foundation**

**Advancing Treatment | Finding Cures**

**Rheumatology Research Foundation Abstract Awards**

The Rheumatology Research Foundation offers award opportunities for medical students, residents, and pediatric rheumatology fellows who submit an abstract for the 2018 ACR/ARHP Annual Meeting by the June 5 submission deadline.

- Award recipients will receive a cash award plus reimbursement of travel expenses to attend the meeting.
- Acceptance of an abstract does not automatically enroll or guarantee receipt of a Foundation abstract award.
- Fellows must submit an abstract to the 2018 ACR/ARHP Annual Meeting by noon ET on June 5 in order to be eligible.
- Application deadline for the Foundation’s abstract awards is Wednesday, August 1, at 5:00 PM ET.
- Visit the Foundation’s [Annual Meeting Awards website](http://www.rheumatology.org/Annual-Meeting/Abstracts) or call 404-633-3777 ext. 318 for complete award details.

Abstract Submission Instructions/Guidelines

**Submitting an Abstract**

- All abstracts must be submitted online.
- Visit the [online submission site](http://www.rheumatology.org/Annual-Meeting/Abstracts) to get started.
- Submitters will be able to access complete submission instructions and guidelines via the online submission site.

**Abbreviations**

- Use standard abbreviations. A list of **acronyms for many common rheumatology terms** has been developed by an international group of rheumatology journal editors.
- Place special or unusual abbreviations in parentheses after the first time the full word appears.
- Do not abbreviate compounds in the title.
- Use numerals to indicate numbers, except when beginning sentences.
Abstract Submission continued

Abstract Character Limit
- **Title** character limit: 250 characters, excluding spaces
- **Body** character limit: 2,750 characters, which EXCLUDES the title, names of authors/co-authors, authors’ affiliations, spacing, and disclosures.
- **Image, table, and/or graphic** limit: There is a limit of three image, table, and/or graphic uploads per submission. Each uploaded table and/or graphic will decrease the character count by 250 characters from the total limit allowed.
- References in the abstract body will be included against the character count.
- Abstracts exceeding the character limit will be considered “incomplete.” Abstracts marked “incomplete” at the close of the submission deadline will be ineligible for review.

Abstract Title
- Enter the title in the title field only and do not enter the title in the body of the abstract.
- Title character limit is 250 characters, excluding spaces.
- Titles DO NOT count toward the 2,750 abstract body character limit.
- Take special care when entering your title, as it may be published exactly as submitted.
- Titles should be brief, clearly indicating the nature of the presentation.
- Include only **commonly used acronyms** in the abstract title.
- Do not include a trial group name or acronym in the abstract title.
- Registry names may be included in the title.
- When entering the title online, use mixed case (do not use all caps OR all lowercase). Do not put a period at the end of the title. For example:

Correct:
This Is a Properly Formatted Abstract Title

Incorrect:
THIS IS AN IMPROPERLY FORMATTED ABSTRACT TITLE
This is an improperly formatted abstract title
This is an imp roperly formatted abstract title.

Authors
- To qualify for authorship, individuals must have made substantial contributions to study conception and design; and/or substantial contributions to acquisition of data; and/or substantial contributions to analysis and interpretation of data.
- **New Policy:** In addition to a presenting author, during submission a submitter will identify an author to be “designated secondary contact author.” The secondary contact author will be contacted if the presenting author is unresponsive after 30 days from first notification.
- Do not list authors or commercial relationships in the body of the abstract.
- Please consult with your co-authors on how their names should appear prior to submission.
  **You will not be able to make changes after the submission deadline.**
- All authors must disclose any relevant financial relationship(s) at the time of submission.
- There is no limit on the number of authors that may be included in the author block.
- See the Disclosure Policy section below for additional author identification instructions.
Abstract Submission

Content

- Do not use new technical words, laboratory slang, words not defined in dictionaries, or abbreviations or terminology not consistent with internationally accepted guidelines.
- Refer to the list of commonly used acronyms for recommendations on acceptable terms for scientific communication.
- Define special or unusual abbreviations the first time they are used.
- Omit all names and geographical references in the body of the abstract.
- Organize content in sections as follows, using the exact section name and colon:
  - **Background/Purpose:** Background or statement of purpose
  - **Methods:** Methods, materials, and analytical procedure used*
  - **Results:** Summary of the results in sufficient detail to support conclusion (never “results will be discussed”)
  - **Conclusion:** Conclusions reached

*Please Note: In order to make the description of patients as clear as possible and to facilitate comparisons with other studies, include a short paragraph in the Methods section detailing the proportion of patients who satisfy the ACR classification criteria for the particular disease.

Images, Tables, and Graphics

- Up to three images are allowed; however, each image/table counts as 250 characters towards your maximum of 2,750 total characters.
- The characters in the table do NOT count towards this limit—each table is worth exactly 250 characters.
- The maximum allowable size of each image is 2.5 MB.
- Images will be accepted as PNG, JPG, or GIF files.
- **If your table exceeds eight (8) columns, please upload it as an image.** This will help us ensure consistent and accurate output of your abstract at time of publication.

**IMPORTANT:** Images, tables, and/or graphics exceeding the total limit of three may be marked “incomplete” at the close of the submission deadline and will be ineligible for review.

Disclosure Policy

- As a CME provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), the ACR must ensure balance, independence, objectivity, and scientific rigor in all its educational activities.
- To this end, the ACR requires that individuals (presenters/speakers, moderators, reviewers, authors, and planners and their spouses/partners) disclose to the planning committee, ACR, and audience any relevant financial relationships with commercial interests that have the potential to affect the content of CME about the products or services of that commercial interest. In the case where such relationships exist, the ACR must resolve the conflict of interest.
- If no relationships exist, individuals **MUST STATE** that **NONE** exists to reflect that the question was asked and answered.
2018 CALL FOR ABSTRACTS GUIDELINES AND PROCEDURES

ABSTRACT SUBMISSION DEADLINE: June 5, noon ET!

www.rheumatology.org/Annual-Meeting/Abstracts

| Abstract Submission continued |

- The ACCME defines **relevant financial relationships** as financial relationships in any amount occurring within the past 12 months for both the individual and/or spouse/partner:
  - **Relevant Financial Relationships**
    - None: Has no relevant financial relationship to disclose.
    - 1. Stock options or bond holdings in a for-profit corporation or self-directed pension plan;
    - 2. Research grants;
    - 3. Employment (full- or part-time);
    - 4. Ownership or partnership;
    - 5. Consulting fees or other remuneration;
    - 6. Non-remunerative positions of influence, such as officer, board member, trustee or public spokesperson;
    - 7. Receipt of royalties;
    - 8. Speakers’ bureau; or
    - 9. Other.
  - **Commercial Interest** is considered any entity producing, marketing, re-selling, or distributing healthcare goods or services consumed by or used on patients.
  - **Conflict of Interest** exists when individuals (within 12 months, including the spouse/partner) have a relevant financial relationship with a commercial interest and the opportunity to affect the content of the CME about the products or services of that commercial interest.

**Disclosure Statement Submission Process**

- If there are relationships that create a conflict of interest, these must be resolved in accordance with the ACR’s CME Resolution of Conflict policy prior to the participation of the individual in the development or presentation of CME content.
- Abstracts will not be eligible for review without proper completion of the conflict of interest/disclosure section on the submission form.
- Failure to disclose correctly may lead to corrective action as deemed appropriate by the ACR or ARHP leadership.
- The abstract review process is blinded. The disclosure information you provide will not influence the review of your abstract.
- Presenting authors are permitted to enter the disclosure information on behalf of each co-author during the online submission process.
- To assist presenting authors and co-authors in deciding what is necessary to disclose online, you may download the ACR CME Disclosure Statement and Attestation Form.
- Each co-author may choose to complete this form and return it to presenting author.
- Keep in mind that all disclosure information must be entered in the online submission site—the ACR does not accept paper disclosure statement forms.
- Accepted disclosures collected at the time of submission will be published on the ACR website.

**Involvement of Individuals Not Listed as Authors**

- Names of all individuals who had a substantial role in the study or abstract preparation but are not included in the list of authors (such as a medical writer) must be disclosed in the body of the abstract.
- For each individual, please describe the activity or activities (e.g., one or more of the activities included in the authorship criteria list).

**Multiple Submissions of the Same Study**

Do not submit the same study as multiple abstracts. If the submitted abstracts are not different enough to be considered separate studies (specifically, if they address the same research question or present the same results), they may all be rejected.
I Abstract Submission  continued

Presentation Formats
- Abstracts are considered for either oral or poster presentation.
- The presenting author need not be the first author, but must be a listed author.
- As English is the designated language for the meeting, the presenting author is required to speak English when presenting.
- For concurrent or plenary sessions, only one author may present the abstract.
- If your abstract can only be presented as a poster, please check the appropriate box during the submission process.

Product Name Usage
- The non-proprietary (generic/scientific) name should be used in your abstract.
- The proprietary drug name may appear once in parentheses in the title only. It may not appear in the body.
- If a drug has not received FDA approval, only the non-proprietary name may be used in the title and abstract content.
- Failure to comply will result in disqualification of your submission.

Research Involving Animals
The Institutional Animal Care and Use Committee (IACUC) of an institution, or a comparable body depending on country, ensures the humane treatment of animals used for research and education. If your research involved animals, you will be required to check a box during the submission process to attest that you have received the appropriate approval.

Research Involving Human Subjects
An Institutional Review Board (IRB), or a comparable ethical review board depending on country, protects the rights and welfare of people involved in research. If your research involved human subjects, you will be required to check a box during the submission process to attest that you have received the appropriate ethical review board approval.

Revisions
- You may return to the online submission site to revise your abstract until noon ET on Tuesday, June 5, 2018.
- After this date/time, the submission site will close and no additional changes, edits, revisions, etc. can be made to the title, content, author, or disclosure information—no exceptions.
- Proofread carefully to avoid errors prior to submission.
- Selected abstracts will be published online exactly as submitted.
- Should a submission contain errors or the omission of contributing author names after the deadline, presenters may opt to have the abstract withdrawn. Refer to the Withdrawals section of this guide for instructions.

Study Design Abstract Submissions
A study design abstract could be appropriate for submission if, like any other submission, it describes a hypothesis, description of methodology, data, interpretation of data, etc. For example, one study design could be compared to another. Submit an abstract to a category based on the disease for which the study design is most relevant.

ABSTRACT SUBMISSION DEADLINE: June 5, noon ET!  www.rheumatology.org/Annual-Meeting/Abstracts
Study Sponsor Statements

- For abstracts about studies that were funded by a pharmaceutical company, biotech company, or other commercial enterprise, a “Role of the Study Sponsor” (or Sponsors) statement must be included.
- This statement describes the commercial entity’s role in the conduct and reporting of the study.

**IMPORTANT:** This applies only to **commercial enterprises**. It does not apply to **government entities** such as the National Institutes of Health (NIH) or its equivalent funding agencies in other countries, or to public or private foundations.
- Study sponsor statements will be published in electronic version only on the [Annual Meeting website](http://www.rheumatology.org/Annual-Meeting/Abstracts).

Withdrawals

- After June 5, presenting authors may submit a request to have an abstract withdrawn.
- All requests for withdrawal can only be made by the **presenting author** and must be submitted via email to: withdrawn@rheumatology.org.
- **Withdrawal requests must include the following:**
  - Abstract ID Number
  - Abstract Title
  - Presenting Author’s Name
- Removal of a withdrawn abstract from the online supplement of *Arthritis & Rheumatology* cannot be guaranteed if the request is received after **Thursday, August 16**.

Need Help?

- For **technical assistance** regarding the abstract submission site, contact The Conference Exchange technical support at 401-334-0220 or via email at acr@confex.com between 8:30 AM and 6:00 PM ET, Monday through Friday.
- For **general guideline inquiries** regarding abstract submission, email abstracts@rheumatology.org.

Abstract Review and Notification

**Abstract Review**

- After the submission deadline, completed abstracts will be peer reviewed by a subsection of the ACR Abstract Selection Committee or the ARHP Annual Meeting Program Subcommittee, according to subject categories.
- Incomplete abstracts cannot be processed and will **not** be reviewed.
- Revisions will not be accepted after the submission deadline—no exceptions.
- All reviewers are required to sign a confidentiality agreement.
- All abstracts will be blinded for review, i.e., reviewed without knowledge of the author(s), institution(s), or disclosure information.
- Accepted abstracts will be selected as either a short oral presentation or a poster presentation.
Abstract Acceptance/Rejection Notifications

Please Note These policies have changed.

• Both presenting authors and co-authors will receive initial notification of acceptance/rejection.
• After initial notification, co-authors will be referred to the presenting author for any additional questions. No further correspondence will occur between the ACR and co-authors. Should the presenting author be unresponsive after 30 days from first notification, ACR staff will contact the designated secondary contact author.

Registration & Housing

• Submission or acceptance of an abstract does not register you or ensure hotel accommodations for the Annual Meeting. All presenting authors are required to register for the meeting, pay the appropriate registration fees, and arrange hotel accommodations.
• As abstract presentation dates will be not be finalized until mid-August, presenting authors should plan to attend the entire meeting.
• Scheduled abstract sessions will not be changed to accommodate travel schedules.
• Registration and housing will open for ACR/ARHP members on Wednesday, May 16, and for non-members on Wednesday, May 30. Learn more about registration and housing on the Annual Meeting website.

PART II: ABSTRACT PRESENTATION

Abstract Embargo Policy

Accepted abstracts are available to the public online in advance of the meeting, and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR/ARHP Annual Meeting abstract website. However, the ACR continues to require that information that goes beyond what is contained in the abstract [e.g., discussion of the abstract done as part of a scientific presentation or presentation of additional new information that will be available at the time of the meeting] is under embargo until 4:30 PM CT on October 20.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the ACR abstract embargo policy, please contact the Annual Meeting abstract staff at abstracts@rheumatology.org.

ABSTRACT SUBMISSION DEADLINE: June 5, noon ET! www.rheumatology.org/Annual-Meeting/Abstracts
II Abstract Presentation continued

Presentation Formats

- Abstracts are considered for either oral presentation or poster presentation.
- As English is the designated language for the meeting, the presenting author is required to speak English when presenting.
- If your abstract can only be presented as a poster, please check the appropriate box during the submission process.
- The acceptance notification email will list the presentation format for each accepted abstract.

Oral Abstract Presentation

- Oral presentations are 15-minute podium presentations.
- The presenter will have 12 minutes for presentation and three minutes for discussion.

**Please Note** Plenary and late-breaking abstract presenters will be asked to stay an extra 15 minutes after their sessions to answer additional questions.

- Oral abstract presenters will be required to bring their presentation in an electronic format to the on-site Speaker Ready Room, where they will have the opportunity to review and/or revise presentations using computers in the room.
- All slides will be checked for adherence to ACCME policies by ACR staff prior to uploading the presentation.
- All presentations will then be uploaded to a central server and sent to the appropriate meeting room on a secured intranet circuit prior to the start of the session.

Oral Presentation Slide Requirements

- Slide #1 must be your title slide.
- Slide #2 must be your disclosure slide. Your disclosure statement should list all commercial relationships relevant to your specific talk. Disclosures must never include the use of a trade name or a product group message.
- Do not reference any company/product brand names during your presentation. However, institution logos (e.g., non-company/product logos such as universities, non-profit associations, and government agencies) are allowed in the body of your presentation.
- Abstracts must not contain any advertising, trade names, or product group messages.
- Presentation slides should be in wide screen (16:9) format.

Poster Abstract Presentation

- Posters are grouped by topic and will be displayed in the poster hall area from Sunday–Tuesday, October 21–23.
- Posters must fit within a 42” x 90” area (106.7 cm x 228.6 cm).
- Posters must be mounted by 8:30 AM and dismantled after 4:00 PM during the designated poster session day as outlined in the abstract poster acceptance notification.
- **IMPORTANT:** The ACR will remove and recycle all posters not picked up by 6:30 PM each day. Unclaimed posters will not be stored.
II Abstract Presentation continued

Poster Specifications:
- The backboard panel for each poster presentation board measures 42 inches (106.7 cm) high and 90 inches (228.6 cm) wide:

- Posters should be printed horizontally and not exceed the size of the presentation board.
- A copy of the accepted abstract must be affixed to the poster or made available to attendees in non-electronic form.
- Text and illustrations must be readable from distances of at least three feet. Use lightweight materials only. Heavy articles may fall off the board.
- Disclosures must never include the use of a trade name or a product group message. List all disclosures once at the bottom of the poster.
- Sponsored abstracts may credit the sponsoring commercial entity in a plain text statement at the bottom of the poster. Product or company logos must never be used. Non-commercial institution (e.g., universities, non-profit associations, and government agencies) logos may appear.
- Posters may be broken down into several smaller portions, but must not exceed the size of the presentation board.
- Push pins to mount materials will be available on site.
- No audiovisual, projection, or computer equipment requiring electrical power will be permitted in the poster session area.
- Poster presenters are permitted to include a QR code on their poster that allows attendees to scan the code and view your uploaded poster as an electronic copy:

QR Code Tips
- A QR code is a two-dimensional barcode that is readable by smartphones. It allows you to encode a PDF of your poster presentation into a two-dimensional barcode in lieu of paper handouts.
- Attendees access the poster from their smartphones by scanning the QR code that you have displayed on your poster.
- To create a QR code, simply search the web for one of the many free online QR code generators.
- **ACR staff will be unable to provide assistance with creating QR codes.**
- QR code readers are available in the Apple App Store and Google Play.

ACR Poster Presenter Expectations
- Hang your posters by 8:30 AM and remove them promptly after 4:00 PM during the designated poster session noted in your abstract acceptance notification. **IMPORTANT:** The ACR will remove and recycle posters that are not picked up by 6:30 PM each day.
- Presenting authors must be available at their poster from 9:00–11:00 AM to answer questions from attendees and poster tour participants.
- The ACR will monitor posters during the presentation hours to make certain that the ACR is meeting the educational needs and expectations of attendees.
- The ACR does not have an official poster printing partner. The ACR will not offer poster printing and hanging services in Chicago, IL.
19

Guided Poster Tours

- Guided poster tours, led by experts in the field, will guide small groups of attendees to selected posters to highlight novel or recent developments.
- If your poster is selected for the tour, the tour guide will contact you before the meeting.

Presenting Author Responsibilities

At the time of submission, a presenting author must be designated. English is the required language for all meeting presentations.

The presenting author will be the sole point of contact for information regarding the submission and is responsible for the following:

- Ensuring each co-author is aware of the content of the abstract and supports its data. Failure to receive approval from each co-author will result in the abstract being disqualified.
- Ensuring each co-author is aware of the disclosure requirements.
- Adhering to the Disclosure Policy and obtaining disclosure information from all co-authors.
- Forwarding ACCME and ACR policies to each co-author.
- Notifying each co-author of any changes to the program, as corresponded by the ACR or ARHP, in a timely manner.
- Presenting the abstract or arranging for a co-author to present the abstract if it is selected. (Only co-authors listed on the accepted abstract may serve as an alternate presenting author.)
- Appointing a co-author to present the abstract in your absence if a schedule conflict is identified before the meeting (for example, if you have accepted an invitation to participate as an invited speaker, moderator, or poster tour guide). The ACR will not collect alternate presenter information or make any presenting author corrections to publications.

ACR Abstract Session Schedule Conflicts Policy

- Abstract session and presentation schedules cannot be changed.
- Invited speaker and moderator schedules cannot be changed to accommodate abstract oral or poster presentations.

Presenting Author Affirmations

- The ACR does not condone presentations given by an invited presenter who has not been intimately involved in the development of the data, or who does not meet the criteria for authorship.
- To be eligible, presenting authors will be required to confirm agreement with the following affirmation statements at the time of submission:
  - I confirm I had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis, and approved the data for presentation.
  - I confirm I made significant contributions to the study design, analysis, or interpretation of results.

ACCME Standard and ACR Policy Regarding Third-Party Bias

- In accordance with ACCME requirements and ACR policy, abstracts selected for oral or poster presentation must be free of bias.
- Do not reference any company/product brand names during your presentation. University, non-profit association, or government agency logos are allowed in the body of your presentation.
- The ACR requires that educational materials that are part of a CME activity, such as slides, abstracts, and handouts, not contain any advertising, trade names, or a product group message.
- Disclosures must never include the use of a trade name or a product group message.
- For oral presentations, disclosures must be listed on the second slide of each presentation.
- For poster presentations, disclosures must be listed once at the bottom of the poster.
II Abstract Presentation continued

Publication
- Accepted abstracts will be published in an online supplement of *Arthritis & Rheumatology*, an official journal of the American College of Rheumatology.
- All accepted abstracts will be available on the Annual Meeting abstract site several weeks before the meeting.

PART III: ABSTRACT PERMISSIONS POLICIES

Copyright Policy
The Annual Meeting is a private event. Programs presented at the meeting are for the education of attendees and purchasers of recorded presentations as authorized by the American College of Rheumatology. The information and materials displayed and presented during this meeting are the property of the ACR and the presenter and cannot be photographed, copied, photocopied, transformed to electronic format, reproduced, or distributed without written permission of the American College of Rheumatology and the presenter. Any use of the program content for commercial purposes, which includes, but is not limited to, oral presentations, audiovisual materials used by speakers, and program handouts, without the written consent of the ACR is prohibited. This policy applies before, during, and after the meeting. The ACR will enforce its intellectual property rights and penalize those who infringe upon it.

Abstract Permissions and Reprints
Copyright law covers all Annual Meeting abstracts published by the American College of Rheumatology. All rights reserved. No abstracts may be reproduced in any form or by any means without the prior permission of the publisher, except as permitted under section 107 and 108 of the 1976 United States Copyright Act.

For the purposes of this statement, the term ACR Abstracts refers to all Annual Meeting abstracts as published in *Arthritis & Rheumatology* and posted online, including the abstracts accepted for presentation during ARHP sessions and the late-breaking category.

For the purposes of this statement, the term ACR Posters refers to the accepted abstract POSTER PRESENTATIONS as presented in the poster hall during the Annual Meeting. This does not include abstract text published in the online supplement of *Arthritis & Rheumatology*. All ACR Posters are the property of the ACR and the presenting author and cannot be reproduced or distributed without written permission from the ACR and the presenting author.

For the purposes of this statement, the term “reproduce” includes all forms of reproduction, including, but not limited to, print, electronic, and photographed formats.

For the purposes of this statement, the term “presenting author” refers to the author who is designated as the individual who will present the work during the ACR/ARHP Annual Meeting, as identified through the abstract submission process.
III Abstract Permissions Policies continued

Approval Process for ACR Abstracts

- Excerpts or the entirety of ACR Abstracts may not be reproduced without the prior written permission of the publisher.
- Permission requests for abstract content and other permission inquiries should be addressed to:

  Permissions Department
  c/o John Wiley & Sons, Inc.
  111 River Street
  Hoboken, NJ 07030
  Fax: 201-748-6008
  wiley.com/go/permissions

- Commercial entities seeking permission to reprint must obtain all materials from the author and/or publisher John Wiley & Sons, Inc. The ACR cannot provide any materials.

Approval Process for ACR Posters

- Reprint requests for the actual poster abstract text published in the Arthritis & Rheumatology supplement are considered ACR Abstracts and must submitted to Wiley (see approval process above).
- Requests to reproduce individual ACR posters, poster figures, or booklets of two or more poster presentations must be submitted via email to abstractreprints@rheumatology.org.
- Poster reproduction requests must include the following:
  - Abstract ID Number
  - Abstract Title
  - Presenting Author’s Name
  - A copy of Presenting Author’s written approval (email approval is acceptable)

Reproducing ACR Abstracts and Posters for Dissemination Prior to the Annual Meeting

- Requests to reproduce abstracts for dissemination prior to the Annual Meeting will not be approved.
- Per the ACR Embargo Policy, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an abstract online.
- Permission to issue a press release does not require ACR approval. However, it must comply with the ACR Embargo Policy; violation of this policy may result in the abstract being withdrawn from the meeting or other measures deemed appropriate.
- For more information regarding press releases, please contact the ACR public relations department at pr@rheumatology.org.

Reproducing ACR Abstracts and Posters for Dissemination During the Annual Meeting

- Following approval (see approval process above), an exhibiting organization may disseminate copies of individual ACR Abstracts from its exhibit space. Booklets of abstracts (e.g., two or more) may not be produced.
- Following approval, an exhibiting organization may disseminate information summaries (title/date/time/poster number) of ACR Abstracts from its exhibit space. Summaries may not reference company or product names. Requests for approval must be submitted in writing to abstractreprints@rheumatology.org.
- Presenting authors may disseminate individual copies of their ACR Poster during their assigned poster presentation time only in the area directly in front of their assigned poster space. This must not interfere with other poster presentations.
- Presenters may provide an electronic copy of the poster via a QR code (see above for more information).
III Abstract Permissions Policies continued

Reproducing ACR Abstracts and Posters for Dissemination After the Annual Meeting

ACR Abstracts
Following approval from Wiley (see approval process above), the ACR permits ACR Abstracts (i.e., all abstract content published in the online supplement) to be reprinted and disseminated following the Annual Meeting.

- Abstracts and booklets of abstracts (e.g., two or more) must include the following statement on the front of the abstract/booklet:
  Abstract(s) reprinted from the ACR/ARHP Annual Meeting held October 19 – 24, 2018. The American College of Rheumatology does not guarantee, warrant, or endorse any commercial products or services. Reprinted by [insert name of supporting company].
- Booklets cannot contain corporate or product logos or any advertisements. No exceptions.

ACR Posters
Following approval from the presenting author and the ACR (see approval process above), copies of actual ACR poster presentations (i.e., images from the poster presentation hung in the poster hall) may be reproduced.

- Reprint requests for the actual poster abstract text published in the Arthritis & Rheumatology supplement are considered ACR Abstracts and must submitted to Wiley (see approval process above).
- IMPORTANT: The ACR does not retain and cannot provide poster presentation images.
- The following statement must be listed under each poster reprint:
  Reprinted from the ACR/ARHP Annual Meeting held October 19 – 24, 2018. The American College of Rheumatology does not guarantee, warrant, or endorse any commercial products or services. Reprinted by [insert name of supporting company].

Media
Credentialed media attend the Annual Meeting to cover stories for consumer, trade, and other media outlets and are easily identified by their black press ribbons. Media has access to all general sessions and limited access (at the discretion of speakers) to Meet the Professor and Workshop sessions. Media may use handheld audio recorders and still cameras (assuming that intellectual property copyrights are respected); moving video recording is also permitted with the permission of the presenter(s). The exception to this policy is that no photos or video are allowed in the Exhibit Hall, or in the Poster Hall without permission from the poster presenter. Press who would like general photos of the Exhibit Hall can obtain these after the meeting from the ACR. For more information about the ACR’s media policies, contact the public relations department at pr@rheumatology.org.

Photographs and Video Recording Policy

ACR policy does not permit photographs or recordings during educational sessions, including poster sessions, without the permission of the presenting author. The only exception to this is for registered media, who should review their registration materials for more information.
III Abstract Permissions Policies continued

Disclosure and Content Use

Use of the ACR Name

The names, insignias, logos, and acronyms of the ACR, the ARHP, and the Rheumatology Research Foundation are proprietary marks. Use of the names in any fashion, by any entity, for any purpose, is prohibited without the express written permission of the American College of Rheumatology.

Use of the ACR Disclosure Key

It is suggested when referencing disclosures in the reprints, that the ACR’s disclosure key be added to provide adequate context for abstracts:

None: Has no financial relationships to disclose
1. Stock options or bond holdings in a for-profit corporation or self-directed pension plan;
2. Research grants;
3. Employment (full- or part-time);
4. Ownership or partnership;
5. Consulting fees or other remuneration;
6. Non-remunerative positions of influence, such as officer, board member, trustee or public spokesperson;
7. Receipt of royalties;
8. Speakers’ bureau; or
9. Other

Use of the ACR Scientific Program Content

• Information displayed or presented at all sessions during the Annual Meeting is the property of the ACR or the presenter. Information may not be recorded, photographed, copied, photocopied, transferred to electronic format, reproduced, or distributed without the prior written permission of the ACR and the presenter.
• Any use of the program content, including all oral presentations, audio-visual materials used by speakers, and program handouts, is prohibited without the written consent of the ACR.
• The ACR’s intellectual property rights policy applies before, during, and after the meeting. Violators may be penalized.
PART IV: ACR CALL FOR LATE-BREAKING ABSTRACTS

The late-breaking abstract category allows for the submission of truly late-breaking scientific research for which no preliminary data are available at the time of the June 5 general abstract submission deadline.

**Attention!** Do not delay your abstract submission! It is in your best interest to submit during the general submission period.

*General Abstract acceptance rate: 80%
Late-Breaking Abstract acceptance rate: 20%

An abstract submitted to the late-breaking category only because the submitter missed the general deadline will not be accepted. A legitimate reason that the abstract could not be submitted during the general abstract submission period is required, and a very high degree of scientific excellence is expected in late-breaking submissions.

**Late-Breaking Abstract Submission**
Thursday, August 16 ............... Late-Breaking Abstract Submission Site Opens
Thursday, September 13 .......... Late-Breaking Abstract Submission Site Closes [noon ET]

Visit the [Annual Meeting website](http://www.rheumatology.org) in July for complete Late-Breaking Abstract guidelines.
2018 IMAGE COMPETITION: CALL FOR IMAGES

Take advantage of the opportunity to have your case-based image reviewed by experts in the field of rheumatology and exhibited in an international venue. If accepted, your image will be uploaded to the ACR’s Rheumatology Image Library and presented at the 2018 ACR/ARHP Annual Meeting in Chicago, IL, on October 19–24.

One winner will be selected to receive complimentary registration to attend the 2018 meeting in Chicago and will be published in an issue of *Arthritis & Rheumatology*!

The submission deadline is June 5 at noon ET.

Visit [https://acr.tw/ACR18CFI](https://acr.tw/ACR18CFI) for more information and to submit an image.
New to the ACR/ARHP Annual Meeting, patients are invited to share their story through the Patient Perspectives Poster Program!

Patients affected by rheumatic disease, along with a sponsoring organization such as a nonprofit patient group or pharmaceutical company, are invited to share adaptations that have improved their health developed from collaboration with their healthcare team, through digital posters at the 2018 ACR/ARHP Annual Meeting!

Accepted submissions will be published online and in *Arthritis & Rheumatology*, and first authors (patients) will be invited to produce a digital poster and provided one-day complimentary registration to attend and present their poster in Chicago, IL on Sunday, Oct. 21.

**The submission deadline is June 5 at noon ET.**

Visit [https://acr.tw/ACR18PP](https://acr.tw/ACR18PP) to learn more.